Navigation Links
Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn's and Colitis Organisation - Inflammatory Bowel Diseases 2017
Date:2/9/2017

SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Dr. Scott Lee and Professor Tanja Kühbacher will present data on etrasimod (APD334) at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) - Inflammatory Bowel Diseases 2017 on Friday, February 17. The conference is taking place February 15-18 at the CCIB Barcelona in Barcelona, Spain. The data are available in the Journal of Crohn's and Colitis, Volume 11, Issue Supplement 1.

The following abstracts will be presented:

Title: Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers Session Type: Poster Presentation Poster Presentation Number: P369 Date: February 17 at 12:30pm CET Location: Poster Exhibition Area

Title: Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator Presenter: Scott Lee Session Type: Digital Oral Presentation Digital Oral Presentation Number: DOP077 Date: February 17 at 5:44pm CET Location: Room 111 – Level 1

Title: Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator Presenter: Tanja Kühbacher Session Type: Digital Oral Presentation Digital Oral Presentation Number: DOP078 Date: February 17 at 5:50pm CET Location: Room 111 – Level 1

About Arena Pharmaceuticals We are a biopharmaceutical company focused on developing novel, small molecule drugs across a range of therapeutic areas. We have three primary proprietary investigational clinical programs: etrasimod (APD334) in Phase 2 evaluation for ulcerative colitis, APD371 entering Phase 2 evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase 2 evaluation for pulmonary arterial hypertension (PAH). Additionally, we have collaborations with the following pharmaceutical companies: Eisai Co., Ltd. and Eisai Inc. (commercial stage), Axovant Sciences Ltd. (Phase 2 candidate), and Boehringer Ingelheim International GmbH (preclinical candidate).

Our US operations are located in San Diego, California. Our primary clinical operations are located in Zug, Switzerland, and our commercial manufacturing for BELVIQ is located in Zofingen, Switzerland.

Forward-Looking Statements Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the upcoming presentations; and Arena's focus, primary programs and collaborations. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include those disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contact: Arena Pharmaceuticals, Inc. Kevin R. Lind, Chief Financial Officer klind@arenapharm.com 858.210.3636

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-announces-three-upcoming-presentations-at-the-12th-congress-of-european-crohns-and-colitis-organisation---inflammatory-bowel-diseases-2017-300404708.html


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Arena Pharmaceuticals Completes Enrollment in Ralinepag Phase 2 Clinical Trial for Pulmonary Arterial Hypertension (PAH)
2. How These Biotechs Stocks are Performing? - Intrexon, Vertex Pharma, Arena Pharma, and Regeneron Pharma
3. Arena Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
4. Arena Pharmaceuticals to Host Fourth Quarter and Full Year 2015 Financial Results and Corporate Update Conference Call and Webcast on Monday, February 29
5. Deloitte Corporate Finance LLC Advises The Marena Group, Inc. on its Recapitalization with The Riverside Company
6. Arena Helps Power IoT Revolution
7. Eisai and Arena Pharmaceuticals Announce FDA Acceptance of New Drug Application for Extended Release Formulation of Lorcaserin
8. Arena Pharmaceuticals to Present at Piper Jaffray 27th Annual Healthcare Conference
9. Arena Pharmaceuticals to Host Analyst & Investor Day on December 3rd
10. Arena Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
11. Arena Pharmaceuticals to Host Third Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2018)... ... November 08, 2018 , ... Keet Health Inc. , ... Payment System (MIPS) Guarantee (1) for outpatient rehab therapists. The MIPS Guarantee ... shielding providers and practices from downward payment adjustment thresholds under the Centers for ...
(Date:11/9/2018)... ... November 08, 2018 , ... The London office ... agreement with Grünenthal to divest the European rights to Nexium for an ... USD90 million. Nexium (esomeprazole) is a proton pump inhibitor that decreases the amount of ...
(Date:11/8/2018)... BEACH, Calif. (PRWEB) , ... ... ... Inc. has expanded its treatment center to include dedicated residential facilities specifically ... recovery risks faced by individuals after the band, bypass or sleeve procedures. ...
Breaking Medicine Technology:
(Date:11/11/2018)... Fla. (PRWEB) , ... November 11, 2018 , ... ... Periodontics & Implant Dentistry held their 4th annual Free Dental Day for Veterans ... help from many dental professionals in the community willing to donate their time ...
(Date:11/9/2018)... ... 2018 , ... Autism Learning Partners (ALP), a national leader ... developmental disabilities, is pleased to announce its expansion to Portland, Oregon. This expansion ... rise in Autism Spectrum Disorder (ASD) diagnoses while also creating jobs for the ...
(Date:11/9/2018)... ... November 09, 2018 , ... Autism ... the treatment of autism and other developmental disabilities, is pleased to announce its ... address the service gap and alarming rise in Autism Spectrum Disorder (ASD) diagnoses ...
(Date:11/9/2018)... ... 08, 2018 , ... Achla Karnani is pleased to announce ... specially-trained team can handle organizing, packing, de-cluttering, moving, resettling, in-person and online estate ... but their services are great for any families or individuals in need of ...
(Date:11/9/2018)... ... November 08, 2018 , ... ... thrilled to provide advanced skin rejuvenation with NovaThreads® , a non-surgical alternative ... pre-loaded with surgical sutures made of polydioxanone (PDO), a fully-dissolvable thread used in ...
Breaking Medicine News(10 mins):